Grosset J - Search Results

1

Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Nuermberger E, Grosset J. Nuermberger E, et al. Among authors: grosset j. Eur J Clin Microbiol Infect Dis. 2004 Apr;23(4):243-55. doi: 10.1007/s10096-004-1109-5. Epub 2004 Mar 13. Eur J Clin Microbiol Infect Dis. 2004. PMID: 15024625 Review.

2

Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.

Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, Nuermberger E. Williams KN, et al. Among authors: grosset jh. Antimicrob Agents Chemother. 2009 Apr;53(4):1314-9. doi: 10.1128/AAC.01182-08. Epub 2008 Dec 15. Antimicrob Agents Chemother. 2009. PMID: 19075058 Free PMC article.

3

Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig.

Ahmad Z, Klinkenberg LG, Pinn ML, Fraig MM, Peloquin CA, Bishai WR, Nuermberger EL, Grosset JH, Karakousis PC. Ahmad Z, et al. J Infect Dis. 2009 Oct 1;200(7):1136-43. doi: 10.1086/605605. J Infect Dis. 2009. PMID: 19686043

4

Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.

Tyagi S, Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, Bishai W, Grosset J. Tyagi S, et al. Among authors: grosset j. Antimicrob Agents Chemother. 2005 Jun;49(6):2289-93. doi: 10.1128/AAC.49.6.2289-2293.2005. Antimicrob Agents Chemother. 2005. PMID: 15917523 Free PMC article.

5

Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.

Rosenthal IM, Williams K, Tyagi S, Peloquin CA, Vernon AA, Bishai WR, Grosset JH, Nuermberger EL. Rosenthal IM, et al. Am J Respir Crit Care Med. 2006 Jul 1;174(1):94-101. doi: 10.1164/rccm.200602-280OC. Epub 2006 Mar 30. Am J Respir Crit Care Med. 2006. PMID: 16574936 Free PMC article.

6

Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG.

Nuermberger EL, Yoshimatsu T, Tyagi S, Bishai WR, Grosset JH. Nuermberger EL, et al. Among authors: grosset jh. Infect Immun. 2004 Feb;72(2):1065-71. doi: 10.1128/IAI.72.2.1065-1071.2004. Infect Immun. 2004. PMID: 14742554 Free PMC article.

7

Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.

Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH. Nuermberger EL, et al. Among authors: grosset jh. Am J Respir Crit Care Med. 2004 Feb 1;169(3):421-6. doi: 10.1164/rccm.200310-1380OC. Epub 2003 Oct 24. Am J Respir Crit Care Med. 2004. PMID: 14578218

8

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.

Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, Vernon AA, Chaisson RE, Bishai WR, Grosset JH. Nuermberger EL, et al. Among authors: grosset jh. Am J Respir Crit Care Med. 2004 Nov 15;170(10):1131-4. doi: 10.1164/rccm.200407-885OC. Epub 2004 Aug 11. Am J Respir Crit Care Med. 2004. PMID: 15306535

9

Latent tuberculosis infection.

Nuermberger E, Bishai WR, Grosset JH. Nuermberger E, et al. Semin Respir Crit Care Med. 2004 Jun;25(3):317-36. doi: 10.1055/s-2004-829504. Semin Respir Crit Care Med. 2004. PMID: 16088473

10

Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.

Rosenthal IM, Williams K, Tyagi S, Vernon AA, Peloquin CA, Bishai WR, Grosset JH, Nuermberger EL. Rosenthal IM, et al. Am J Respir Crit Care Med. 2005 Dec 1;172(11):1457-62. doi: 10.1164/rccm.200507-1072OC. Epub 2005 Sep 1. Am J Respir Crit Care Med. 2005. PMID: 16141439 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

399 results

Search Page